Business Context and Reporting Period
This Form 8-K reports on the annual meeting of stockholders for Abeona Therapeutics Inc. held virtually on May 19, 2025. The company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market under the symbol ABEO.
Key Financial Metrics
This filing is a current report regarding corporate governance events and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
The filing details the outcomes of three proposals submitted to security holders:
- Proposal 1: Election of Directors. Mark J. Alvino, Faith L. Charles, and Donald A. Wuchterl were elected as Class 3 directors.
- Mark J. Alvino: 26,260,868 votes for; 1,143,117 votes against.
- Faith L. Charles: 26,774,705 votes for; 629,378 votes against.
- Donald A. Wuchterl: 26,856,990 votes for; 546,976 votes against.
- Proposal 2: Advisory Vote on Executive Compensation. The proposal was approved with 25,777,223 votes for and 1,552,881 votes against.
- Proposal 3: Ratification of Auditors. The appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was approved with 34,334,516 votes for and 30,147 votes against.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors beyond the standard disclosure of voting results.
Investor Verification Checklist
- Verify the tenure of the newly elected Class 3 directors (Mark J. Alvino, Faith L. Charles, Donald A. Wuchterl) through the 2028 annual meeting.
- Confirm the engagement of Deloitte & Touche LLP for the fiscal year ending December 31, 2025.
- Review the company's most recent 10-K or 10-Q filings for financial performance data, as this 8-K contains no financial metrics.
- Note the significant number of broker non-votes (7,020,555) recorded for all proposals.